Epidemiology of Invasive Candidiasis and Challenges for the Mycology Laboratory: Specificities of Candida glabrata

[1]  J. Schrenzel,et al.  Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Sw , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  P. Escribano,et al.  Molecular Identification and Antifungal Susceptibility of Yeast Isolates Causing Fungemia Collected in a Population-Based Study in Spain in 2010 and 2011 , 2013, Antimicrobial Agents and Chemotherapy.

[3]  J. Rello,et al.  Epidemiology, Species Distribution, Antifungal Susceptibility, and Outcome of Candidemia across Five Sites in Italy and Spain , 2013, Journal of Clinical Microbiology.

[4]  B. Wickes,et al.  Rapid Emergence of Echinocandin Resistance in Candida glabrata Resulting in Clinical and Microbiologic Failure , 2013, Antimicrobial Agents and Chemotherapy.

[5]  P. Ljungman,et al.  Candidaemia in Sweden: a nationwide prospective observational survey. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  J. Echevarria,et al.  Epidemiology of Candidemia in Latin America: A Laboratory-Based Survey , 2013, PloS one.

[7]  L. R. Ásmundsdóttir,et al.  Nationwide Study of Candidemia, Antifungal Use, and Antifungal Drug Resistance in Iceland, 2000 to 2011 , 2012, Journal of Clinical Microbiology.

[8]  M. Bassetti,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  T. Calandra,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  T. Calandra,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  C. D. de Koster,et al.  Carbon source-induced reprogramming of the cell wall proteome and secretome modulates the adherence and drug resistance of the fungal pathogen Candida albicans , 2012, Proteomics.

[12]  L. Harrison,et al.  Species Identification and Antifungal Susceptibility Testing of Candida Bloodstream Isolates from Population-Based Surveillance Studies in Two U.S. Cities from 2008 to 2011 , 2012, Journal of Clinical Microbiology.

[13]  M. Arendrup,et al.  EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  C. Viscoli,et al.  ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients , 2012, Bone Marrow Transplantation.

[15]  M. Pfaller,et al.  The changing epidemiology of healthcare-associated candidemia over three decades. , 2012, Diagnostic microbiology and infectious disease.

[16]  M. Castanheira,et al.  Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrata , 2012, Journal of Clinical Microbiology.

[17]  P. Nightingale,et al.  Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[18]  M. Antonelli,et al.  Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index , 2011, Critical care.

[19]  P. Pappas.  Candidemia in the intensive care unit: miles to go before we sleep. , 2011, Critical care medicine.

[20]  T. Calandra,et al.  The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia , 2010, Critical care.

[21]  M. Pfaller,et al.  Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and Micafungin , 2010, Journal of Clinical Microbiology.

[22]  L. Leibovici,et al.  PCR Diagnosis of Invasive Candidiasis: Systematic Review and Meta-Analysis , 2010, Journal of Clinical Microbiology.

[23]  F. Dromer,et al.  Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients , 2010, Antimicrobial Agents and Chemotherapy.

[24]  Ronald N. Jones,et al.  Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009) , 2010, Journal of Clinical Microbiology.

[25]  M. Falagas,et al.  Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[26]  V. Anttila,et al.  Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007 , 2010, BMC infectious diseases.

[27]  H. Schønheyder,et al.  National Surveillance of Fungemia in Denmark (2004 to 2009) , 2010, Journal of Clinical Microbiology.

[28]  A. Law,et al.  A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. , 2010, The Journal of antimicrobial chemotherapy.

[29]  J. Sobel.  Changing trends in the epidemiology of Candida blood stream infections: a matter for concern? , 2010, Critical care medicine.

[30]  D. Kontoyiannis,et al.  Caspofungin-non-susceptible Candida isolates in cancer patients. , 2010, The Journal of antimicrobial chemotherapy.

[31]  C. Hennequin,et al.  Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient , 2009, Antimicrobial Agents and Chemotherapy.

[32]  S. Koo,et al.  Diagnostic performance of the (1-->3)-beta-D-glucan assay for invasive fungal disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  M. Bassetti,et al.  Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. , 2009, The Journal of antimicrobial chemotherapy.

[34]  D. Marriott,et al.  Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[35]  A. Horvath,et al.  Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. , 2009, Clinical chemistry.

[36]  J. Bishop,et al.  Identification of Candida nivariensis and Candida bracarensis in a Large Global Collection of Candida glabrata Isolates: Comparison to the Literature , 2009, Journal of Clinical Microbiology.

[37]  M. Melhem,et al.  In vitro susceptibility of Cryptococcus gattii clinical isolates. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[38]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  J. Sch.  GRADE: grading quality of evidence and strength of recommendations for diagnostic tests and strategies , 2008, BMJ : British Medical Journal.

[40]  H. Schønheyder,et al.  Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[41]  D. Denning,et al.  EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts: Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST)∗ , 2008 .

[42]  S. Costa-de-Oliveira,et al.  A first Portuguese epidemiological survey of fungaemia in a university hospital , 2008, European Journal of Clinical Microbiology & Infectious Diseases.

[43]  Subcommittee on Antifungal Susceptibility Testing.  EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[44]  W. Graninger,et al.  Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of Vienna, Austria. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[45]  K. Laupland,et al.  Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. , 2007, The Journal of antimicrobial chemotherapy.

[46]  M. Pfaller,et al.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing , 2007, Journal of Clinical Microbiology.

[47]  J. Meis,et al.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing , 2007, Journal of Clinical Microbiology.

[48]  D. Newton,et al.  To Test or Not To Test: a Cost Minimization Analysis of Susceptibility Testing for Patients with Documented Candida glabrata Fungemias , 2007, Journal of Clinical Microbiology.

[49]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[50]  D. Stevens,et al.  Escape of Candida from Caspofungin Inhibition at Concentrations above the MIC (Paradoxical Effect) Accomplished by Increased Cell Wall Chitin; Evidence for β-1,6-Glucan Synthesis Inhibition by Caspofungin , 2006, Antimicrobial Agents and Chemotherapy.

[51]  L. Bevanger,et al.  Candidemia in Norway (1991 to 2003): Results from a Nationwide Study , 2006, Journal of Clinical Microbiology.

[52]  S. Fridkin,et al.  Evaluation of Amphotericin B Interpretive Breakpoints for Candida Bloodstream Isolates by Correlation with Therapeutic Outcome , 2006, Antimicrobial Agents and Chemotherapy.

[53]  M. Arendrup,et al.  Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  M. Pfaller,et al.  Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing , 2006, Clinical Microbiology Reviews.

[55]  M. J. Buitrago,et al.  Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi , 2006, Antimicrobial Agents and Chemotherapy.

[56]  S. Filler,et al.  Current treatment strategies for disseminated candidiasis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  M. Pfaller.  Antifungal susceptibility testing methods. , 2005, Current drug targets.

[58]  Michael Y. Lin,et al.  Prior Antimicrobial Therapy and Risk for Hospital-Acquired Candida glabrata and Candida krusei Fungemia: a Case-Case-Control Study , 2005, Antimicrobial Agents and Chemotherapy.

[59]  C. Kauffman,et al.  Candida glabrata fungemia: experience in a tertiary care center. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  A. Zaas,et al.  Echinocandins: role in antifungal therapy, 2005 , 2005, Expert opinion on pharmacotherapy.

[61]  J. Guarro,et al.  Phenotypic and Molecular Characterization of Candida nivariensis sp. nov., a Possible New Opportunistic Fungus , 2005, Journal of Clinical Microbiology.

[62]  P. White,et al.  Comparison of Non-Culture-Based Methods for Detection of Systemic Fungal Infections, with an Emphasis on Invasive Candida Infections , 2005, Journal of Clinical Microbiology.

[63]  Yun-Liang Yang,et al.  Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. , 2005, Diagnostic microbiology and infectious disease.

[64]  B. Arthington-Skaggs,et al.  Rapid Acquisition of Stable Azole Resistance by Candida glabrata Isolates Obtained before the Clinical Introduction of Fluconazole , 2005, Antimicrobial Agents and Chemotherapy.

[65]  J. Pemán,et al.  Patterns of Amphotericin B Killing Kinetics against Seven Candida Species , 2004, Antimicrobial Agents and Chemotherapy.

[66]  Lee H. Harrison,et al.  Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program , 2004, Journal of Clinical Microbiology.

[67]  J. Rex,et al.  Determination of Fungicidal Activities against Yeasts and Molds: Lessons Learned from Bactericidal Testing and the Need for Standardization , 2004, Clinical Microbiology Reviews.

[68]  O. Faure,et al.  Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[69]  J. Sobel,et al.  Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  D. Pittet,et al.  Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. , 2003, The Lancet. Infectious diseases.

[71]  Yee-Chun Chen,et al.  Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. , 2003, The Journal of antimicrobial chemotherapy.

[72]  D. Denning,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Microbiology Standards of Care British Society for Medical Mycology Proposed Standards of Care for Patients with Invasive Fungal Infections , 2022 .

[73]  H. Richet,et al.  Candidemia in French hospitals: incidence rates and characteristics. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[74]  D. Poulain,et al.  Contribution of Serological Tests and Blood Culture to the Early Diagnosis of Systemic Candidiasis , 2001, European Journal of Clinical Microbiology and Infectious Diseases.

[75]  A. Favel,et al.  Improved Detection of Amphotericin B-Resistant Isolates of Candida lusitaniae by Etest , 2001, Journal of Clinical Microbiology.

[76]  M. Richardson,et al.  Clinical and laboratory diagnosis. , 2000, Hospital medicine.

[77]  R. Pinner,et al.  The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[78]  M. Henman,et al.  Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro , 1997, Antimicrobial agents and chemotherapy.

[79]  T. Ekfors,et al.  THE USE OF IMMUNOHISTOCHEMISTRY TO IMPROVE SENSITIVITY AND SPECIFICITY IN THE DIAGNOSIS OF SYSTEMIC MYCOSES IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES , 1997, The Journal of pathology.

[80]  Viviane Maria de Carvalho Hessel Dias,et al.  Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals. , 2013, Medical mycology.

[81]  H. Schønheyder,et al.  National Surveillance of Fungemia in Denmark 2010-11 , 2012 .

[82]  Ronald N. Jones,et al.  Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). , 2011, Diagnostic microbiology and infectious disease.

[83]  Aseem Kumar,et al.  Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006) , 2010 .

[84]  C. Pais,et al.  Epidemiology of candidemia in oncology patients: a 6-year survey in a Portuguese central hospital. , 2010, Medical mycology.

[85]  S. James,et al.  Candida bracarensis sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata. , 2006, International journal of systematic and evolutionary microbiology.

[86]  M. Pfaller,et al.  Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[87]  ohn,et al.  COMPARISON OF CASPOFUNGIN AND AMPHOTERICIN B FOR INVASIVE CANDIDIASIS , 2002 .